Show simple item record

Is spurious penicillin allergy a major public health concern only in high-income countries

dc.contributor.authorKrishna, Mamidipudi Thirumala
dc.contributor.authorVedanthan, Pudupakkam K.
dc.contributor.authorVedanthan, Rajesh
dc.contributor.authorEl Shabrawy, Reham Mohamed
dc.contributor.authorMadhan, Ramesh
dc.contributor.authorNguyen, Hoa L
dc.contributor.authorKudagammana, Thushara
dc.contributor.authorWilliams, Iestyn
dc.contributor.authorKarmacharya, Biraj
dc.contributor.authorHariharan, Seetharaman
dc.contributor.authorKrishnamurthy, Kandamaran
dc.contributor.authorSumantri, Stevent
dc.contributor.authorElliott, Rachel
dc.contributor.authorMahesh, Padukudru Anand
dc.contributor.authorMarriott, John F.
dc.date2022-08-11T08:10:00.000
dc.date.accessioned2022-08-23T16:51:42Z
dc.date.available2022-08-23T16:51:42Z
dc.date.issued2021-05-20
dc.date.submitted2021-08-26
dc.identifier.citation<p>Krishna MT, Vedanthan PK, Vedanthan R, El Shabrawy RM, Madhan R, Nguyen HL, Kudagammana T, Williams I, Karmacharya B, Hariharan S, Krishnamurthy K, Sumantri S, Elliott R, Mahesh PA, Marriott JF. Is spurious penicillin allergy a major public health concern only in high-income countries? BMJ Glob Health. 2021 May;6(5):e005437. doi: 10.1136/bmjgh-2021-005437. PMID: 34016579; PMCID: PMC8141433. <a href="https://doi.org/10.1136/bmjgh-2021-005437">Link to article on publisher's site</a></p>
dc.identifier.issn2059-7908 (Linking)
dc.identifier.doi10.1136/bmjgh-2021-005437
dc.identifier.pmid34016579
dc.identifier.urihttp://hdl.handle.net/20.500.14038/41909
dc.description.abstractInaccurate penicillin allergy labels (PALs) are a major public health problem in high-income countries and has been linked to antimicrobial resistance (AMR) and huge healthcare costs. Data regarding epidemiology of PALs and its potential association with AMR is sparse in low-income countries (LICs), low-middle-income countries (LMICs) and upper-middle-income countries (UMICs). There are no established drug allergy labelling and delabelling pathways in the majority of the LICs, LMICs and UMICs and addressing these inequities is critical for safe clinical practice and in the global campaign against AMR. A standardised validated computerised decision support tool might help address these gaps, but understanding local factors including clinical governance, cultural, social, religious and human behaviour will be key to uptake and success of such an intervention.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=34016579&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsCopyright © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjecthealth education and promotion
dc.subjecthealth systems
dc.subjectmedical microbiology
dc.subjectpublic health
dc.subjectInaccurate penicillin allergy labels
dc.subjectantimicrobial resistance
dc.subjectdrug allergy labelling
dc.subjectAllergy and Immunology
dc.subjectHealth Services Administration
dc.subjectImmune System Diseases
dc.subjectInternational Public Health
dc.subjectMedical Microbiology
dc.subjectPublic Health Education and Promotion
dc.titleIs spurious penicillin allergy a major public health concern only in high-income countries
dc.typeJournal Article
dc.source.journaltitleBMJ global health
dc.source.volume6
dc.source.issue5
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=5749&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/4716
dc.identifier.contextkey24508968
refterms.dateFOA2022-08-23T16:51:42Z
html.description.abstract<p>Inaccurate penicillin allergy labels (PALs) are a major public health problem in high-income countries and has been linked to antimicrobial resistance (AMR) and huge healthcare costs. Data regarding epidemiology of PALs and its potential association with AMR is sparse in low-income countries (LICs), low-middle-income countries (LMICs) and upper-middle-income countries (UMICs). There are no established drug allergy labelling and delabelling pathways in the majority of the LICs, LMICs and UMICs and addressing these inequities is critical for safe clinical practice and in the global campaign against AMR. A standardised validated computerised decision support tool might help address these gaps, but understanding local factors including clinical governance, cultural, social, religious and human behaviour will be key to uptake and success of such an intervention.</p>
dc.identifier.submissionpathoapubs/4716
dc.contributor.departmentDivision of Epidemiology, Department of Population and Quantitative Health Sciences
dc.source.pagese005437


Files in this item

Thumbnail
Name:
e005437.full.pdf
Size:
486.8Kb
Format:
PDF
Download

This item appears in the following Collection(s)

Show simple item record

Copyright © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
Except where otherwise noted, this item's license is described as Copyright © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.